CECOG Academy

www.cecog.org

 

Pancreatic Cancer
31:05

CECOG Academy

Modern Treatment Approaches in mPDAC: Overview of 1L/2L Options and Continuum of Care

FEATURING Gerald Prager
  • 183 views
  • July 22, 2021
23:51

CECOG Academy

2021 ASCO Paradigm Changing Updates on Pancreatic Ductal Adenocarcinoma: Considering Clinical Trial Data

FEATURING Talia Golan
  • 38 views
  • July 6, 2021
35:20

CECOG Academy

2021 ASCO Abstracts Review in PAD: Palliative Care, Neoadjuvant Treatment, and Molecular Profiling

FEATURING Talia Golan, Gerald Prager, Changhoon Yoo, Eric Van Cutsem
  • 48 views
  • July 6, 2021
28:06

CECOG Academy

Molecular Testing for Treatment Stratification on PDAC Patients: Where Do We Stand, Where Do We Go?

FEATURING Cindy Neuzillet, Pascal Hammel, Masafumi Ikeda
  • 573 views
  • June 11, 2021
  • 7
30:57

CECOG Academy

PDAC Expert Panel Discussion: Differences in Clinical Practice, Turnaround Time for Molecular Profiles, Surgical & Chemo 1L/2L Options

FEATURING Cindy Neuzillet, Pascal Hammel, Masafumi Ikeda
  • 27 views
  • June 11, 2021
23:53

CECOG Academy

mPAC Oligometastatic Disease Expert Discussion: Eligibility for 2nd Resection, Systemic Therapy Choices for Liver Mets, Time for Surgery, Importance of TRG

FEATURING Thomas Seufferlein, Massimo Falconi, Katsuhiko Uesaka
  • 17 views
  • May 13, 2021
30:28

CECOG Academy

Updates on mPAC: Is There a Target Group for Oligometastatic Disease? Biomarker Data, ctDNA, Surgery and Survival Data, Locoregional Treatment in mPDAC, QoL

FEATURING Thomas Seufferlein
  • 81 views
  • May 5, 2021
31:35

CECOG Academy

Expert Discussion on Resectable/Borderline-Resectable PAC: Gemcitabine in Neoadjuvant Setting, Paclitaxel-Gemcitabine, Adjuvant QT + RT in R1 Resected Tumors

FEATURING Gerald Prager, Teresa Macarulla, Eric Van Cutsem, Chee Cheng Ean
  • 100 views
  • March 31, 2021
23:59

CECOG Academy

Neoadjuvant Treatment Concepts for Resectable/Borderline-Resectable PAC: Is There a Difference Between Gem-Nab and mFOLFIRINOX? Is There a Role for RT?

FEATURING Teresa Macarulla
  • 151 views
  • March 31, 2021
  • 1
29:00

CECOG Academy

Expert Discussion on PRODIGE 24 Data on FOLFIRINOX vs. Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

FEATURING Gerald Prager, Julien Taieb, Harpreet Wasan, Joon Oh Park
  • 373 views
  • March 31, 2021
  • 5
26:51

CECOG Academy

Adjuvant Treatment Options for PAC Patients: Who Should Receive FOLFIRINOX and For How Long? How Effective Is Gemcitabine?

FEATURING Julien Taieb
  • 109 views
  • March 31, 2021
  • 1